SYK launches Mako RPS, expanding into handheld robotics for total knee replacement and broadening access to robotic-assisted orthopedic procedures.
Stryker Corporation offers a compelling medtech investment, benefiting from robust industry growth and an innovation-led strategy. SYK trades at a 13% discount to fair value, with a forward P/E of 20.1 versus a 10-year average of 25.6. Consensus expects SYK's adjusted diluted EPS to compound at 11.2% annually through 2028, supporting high single-digit dividend growth.
Stryker is a Dividend Aristocrat with 32 years of increases, robust cash flow, and a strong M&A-driven growth strategy. SYK's Q1 2026 results were impacted by a cybersecurity incident, but management maintained full-year guidance and expects normalization. The stock trades at ~21x 2026E EPS, below its 5-year average, suggesting undervaluation despite recent share price declines.
Stryker (NYSE:SYK | SYK Price Prediction) and Intuitive Surgical (NASDAQ:ISRG) both closed the books on Q1 2026 with sharply different results.
Stryker (SYK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Stryker faces cyberattack fallout, but strong procedure demand, record Mako adoption and global expansion continue to support long-term growth.
SYK launches TPX HD, a small bone power tool built for complex revisions, MIS and oral maxillofacial cases with higher torque and speed.
SYK launches Pangea Plating System in Europe, completing its first London case as it broadens trauma care solutions for many fractures.
Stryker Corporation (SYK) Presents at Bank of America Global Healthcare Conference 2026 Transcript
SYK misses Q1 earnings and revenue estimates as a cyber incident disrupts production, dents margins, and slows growth despite gains across key segments.
Stryker Corporation (SYK) Q1 2026 Press Conference Call Transcript
While the top- and bottom-line numbers for Stryker (SYK) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.